AI in drug discovery: from hypothetical to reality
As AI-designed drugs begin to enter clinical trials, can it truly deliver on its promise to transform pharmaceutical R&D?
Artificial Intelligence
Lisata collaborates with GATC Health on drug development
Juvenescence enhances AI drug discovery with Ro5 acquisition
Pharma’s AI prospects get nudged into the future with EU’s AI act
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
